Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
Retrieved on:
Friday, January 6, 2023
MHSC, Clinical trial, Fibrosis, Drug development, NASH, Inflammation, Cirrhosis, Table, Doctor's visit, Risk, Elastography, Disease, University of Oxford, Patient, Fatty liver disease, Marie Cassidy, 0,1-simple lattice, University, FDA, Therapy, NAS, Conference, University of California, San Diego, Steatohepatitis, Steatosis, Principal, Liver, Biopsy, Medical imaging, Pharmaceutical industry, Madrigal, NAFLD
The new MAESTRO-NASH data are being presented at the NASH-TAG Conference, taking place from January 5-7, 2023 in Park City, Utah.
Key Points:
- The new MAESTRO-NASH data are being presented at the NASH-TAG Conference, taking place from January 5-7, 2023 in Park City, Utah.
- An MRI-PDFF conducted during screening confirmed that patients had NAFLD prior to obtaining a liver biopsy.
- Each pathologist's scores showed a similar statistically significant magnitude of response at both doses for both liver biopsy endpoints.
- The consensus read by the two central pathologists reinforced the positive results observed in the primary analysis (Tables 1-2).